Depression and Weight Clinical Evidence and Research: What the Studies Show

Introduction

The depression-weight relationship has accumulated a substantial body of research over the past two decades. Some studies are foundational. Some are refinements. Some are recent additions that have changed clinical practice. This is a structured tour of the most relevant evidence, what it shows, and what its limits are.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Luppino 2010: The Bidirectional Link

The Luppino 2010 meta-analysis, published in the Archives of General Psychiatry, established that depression and obesity raise the risk of each other in longitudinal data. The study pooled 15 prospective studies covering over 58,000 participants.

Quick Answer: The Luppino 2010 meta-analysis pooled 15 longitudinal studies showing 58% increased obesity risk from depression and 55% increased depression risk from obesity.

The analysis separated two questions:

1. Does depression at baseline predict obesity later?
2. Does obesity at baseline predict depression later?

Both directions showed significant relationships. Depression at baseline raised obesity risk by 58% (OR 1.58, 95% CI 1.33-1.87). Obesity at baseline raised depression risk by 55% (OR 1.55, 95% CI 1.22-1.98). Effects were stronger in women and stronger for unipolar depression than for milder depressive symptoms.

The findings persisted after adjustment for age, education, income, smoking, and physical activity in most included studies. They’ve been replicated in subsequent meta-analyses including Mannan 2016 in Asian Pacific Journal of Public Health and Mansur 2015 in Neuroscience and Biobehavioral Reviews.

Why it matters clinically: the relationship is real, bidirectional, and not explainable by simple confounding. Treating either condition with an eye to the other improves outcomes.

Limits: observational studies can’t prove causation. Diagnostic criteria varied across included trials. Genetic and environmental confounders weren’t always fully addressed.

Domecq 2015: The Antidepressant Weight Ranking

The Domecq 2015 systematic review and meta-analysis, published in the Journal of Clinical Endocrinology and Metabolism, ranked common antidepressants by their effect on weight. The review included 257 randomized controlled trials and observational studies.

Key findings:

• Amitriptyline produced the largest weight gain in pooled estimates
• Mirtazapine and paroxetine produced consistently significant weight gain
• Bupropion produced weight loss in pooled analyses
• Fluoxetine produced acute weight loss with attenuation over longer follow-up
• Sertraline, escitalopram, citalopram showed modest weight gain

The pooled effect sizes:

• Amitriptyline: +1.8 kg average difference vs placebo at 6 months
• Mirtazapine: +1.7 kg
• Paroxetine: +1.2 kg
• Sertraline: +0.5 kg
• Bupropion: -1.1 kg
• Fluoxetine: -0.8 kg short-term, near-neutral long-term

The review didn’t capture every newer drug. Vortioxetine has been studied since and appears roughly weight-neutral. Newer atypical agents like dextromethorphan-bupropion (Auvelity) inherit bupropion’s profile.

Clinical implication: drug choice meaningfully affects weight outcomes over months and years. Patients with weight concerns benefit from preferential use of bupropion or fluoxetine when other clinical factors allow.

Limits: pooled estimates obscure individual variation. Reporting of weight in psychiatric trials is often incomplete or non-standardized.

SMILES Trial 2017: Diet as Primary Depression Treatment

The SMILES trial (Supporting the Modification of lifestyle In Lowered Emotional States), published by Jacka and colleagues in BMC Medicine in 2017, was the first randomized controlled trial of dietary change as primary treatment for major depression.

Sixty-seven adults with moderate to severe major depressive disorder were randomized to:

• Modified Mediterranean dietary intervention with seven dietitian sessions
• Social support befriending (no diet component)

Both groups received their existing care (medication, therapy, or both) without modification.

At 12 weeks:

• Diet group: 32% achieved remission (MADRS ≤10)
• Social support group: 8% achieved remission
• Effect size for depression score change: large (Cohen’s d = 1.16)
• Drop-out rates were similar between groups

The dietary pattern emphasized vegetables (6 servings/day), fruits (3 servings/day), legumes (3-4/week), whole grains (5-8 servings/day), low-fat unsweetened dairy (2-3/day), raw nuts (1 serving/day), fish (≥2/week), lean meats (3-4/week), eggs, and olive oil. It reduced sweets, refined cereals, fried food, fast food, processed meats, and sugary drinks.

Replication has been partial. The HELFIMED trial in 2017 showed similar directional effects in 152 adults. The AMMEND trial in young adults (2022) also showed benefit. Other dietary depression trials have been smaller and less conclusive.

Limits: small sample size, single-blind design, possible therapist effects in dietary group, and short follow-up.

Clinical implication: dietary intervention belongs in the treatment menu, not as a replacement for medication or therapy in moderate-severe cases, but as a meaningful adjunct.

STAR*D 2006: The Reality of Treatment-resistant Depression

**The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, published in 2006 in the American Journal of Psychiatry, was the largest real-world depression treatment study ever conducted.** Over 4,000 outpatients with major depression were enrolled and followed through up to four sequential treatment levels.

Level 1: Citalopram. About 33% achieved remission, 47% had clinically meaningful response.

Level 2: Patients who didn’t remit could switch to another medication or augment. Cumulative remission rose to about 50% across the first two levels.

Level 3 and 4: Further switches and augmentation. Cumulative remission reached 67% by the end of the protocol.

Key findings beyond response rates:

• Each step yielded smaller incremental gains
• Patients who remitted earlier had better long-term outcomes
• Drop-out increased with each level
• No single second-step strategy was clearly best

STAR*D has been criticized on methodology and reanalysis grounds. A 2023 reanalysis in BMJ Mental Health by Pigott and colleagues argued that more conservative outcome definitions yielded substantially lower remission rates than originally reported. The clinical interpretation remains debated.

Clinical implication: roughly one-third to one-half of patients don’t fully respond to first-line antidepressants, and persistence with sequential trials produces additional gains for many. After two failed adequate trials, augmentation strategies, TMS, esketamine, or specialty consultation become reasonable.

Cooney 2013 Cochrane: Exercise as Depression Treatment

The Cooney 2013 Cochrane systematic review pooled 39 randomized trials of exercise in adults with depression. Total participants exceeded 2,300 across the included studies.

The pooled standardized mean difference for exercise versus no treatment was -0.62 (95% CI -0.81 to -0.42), a moderate effect favoring exercise. Compared with psychological or pharmacological treatment, exercise was non-inferior in many head-to-head comparisons, though trial sizes were small.

The review’s authors urged caution. When the analysis was restricted to higher-quality trials with adequate methodological controls, the effect size dropped to -0.18, a small effect. The reviewers concluded exercise has moderate effects in less rigorous trials and small effects in better-controlled trials.

The 2023 Singh et al. umbrella review in the British Journal of Sports Medicine pooled 97 systematic reviews, covering over 1,000 trials, and concluded that exercise produces clinically meaningful antidepressant effects across multiple modalities (aerobic, resistance, mind-body) and depression severities. The review supported exercise as a first-line treatment.

The Gordon 2018 meta-analysis in JAMA Psychiatry focused specifically on resistance training. It pooled 33 trials and found a moderate effect size (-0.66 SMD) for resistance training in depression, similar to aerobic exercise.

Clinical implication: exercise has real antidepressant effects, especially in mild to moderate depression, with effect sizes that often compete with pharmacotherapy. Both aerobic and resistance training help.

Adams 2018: Bariatric Surgery and Suicide Risk

Adams and colleagues’ 2018 follow-up of the Utah Obesity Study, published in JAMA Surgery, examined long-term mortality and psychiatric outcomes in 1,156 patients who underwent gastric bypass surgery, compared with 1,257 matched non-surgical controls.

Surgical patients had substantially lower all-cause mortality over follow-up averaging 12 years (hazard ratio 0.60). Cardiovascular and cancer mortality were lower. But suicide rates were modestly elevated in the surgical group (1.5% vs 0.9% over follow-up).

Subsequent studies have largely replicated this pattern. A 2020 systematic review in Obesity Surgery found bariatric surgery produces meaningful improvements in average depression scores but also documented elevated suicide risk in the post-surgical period, particularly in the first three years.

Possible mechanisms:

• Altered drug pharmacokinetics affecting psychiatric medications
• Development or worsening of alcohol use disorder post-surgery
• Unmasking of underlying psychiatric vulnerability when food coping is removed
• Body image and weight regain disappointment
• Inadequate psychological support post-surgery

Clinical implication: bariatric surgery is overall life-extending in eligible patients, but psychiatric screening and ongoing post-surgical mental health support are essential. Patients with active psychiatric instability should generally be stabilized before surgery.

FDA 2024 GLP-1 Suicidality Review

In January 2024, the FDA released the conclusions of its review of GLP-1 receptor agonists and suicidality. The review was prompted by reports from European regulators of suicidal ideation cases in GLP-1 users.

The FDA examined:

• Adverse event reports from FAERS database
• Outcomes data from completed clinical trials
• Observational and post-marketing studies

Their conclusion: the available evidence did not support a causal link between GLP-1 receptor agonists and suicidal thoughts or behaviors. They acknowledged ongoing surveillance.

The European Medicines Agency reached a similar conclusion in April 2024.

Subsequent observational data have largely been reassuring. The Wang 2024 retrospective cohort study from Case Western Reserve, published in Nature Medicine, examined over 240,000 patients with overweight or obesity. Semaglutide users had 49-73% lower hazard of new suicidal ideation compared with users of other anti-obesity medications.

A separate analysis of over 1.5 million electronic health records compared semaglutide users with type 2 diabetes against users of other glucose-lowering drugs, with similar directional findings.

Clinical implication: GLP-1 medications appear safe to use in patients with depression history, including those on antidepressant medications. Mood monitoring at baseline and during treatment remains appropriate.

Limits: retrospective data can’t establish causation. The reduced rates of suicidal ideation in semaglutide users could reflect indication bias (clinicians selecting healthier patients for these drugs) or other unmeasured confounding. Randomized data on this specific question doesn’t exist.

Emerging Research on GLP-1s and Mood

Beyond safety, emerging research is examining whether GLP-1 medications might actively benefit mood. Mechanistic plausibility includes anti-inflammatory effects, weight loss benefits, and direct CNS receptor activity in mood-relevant brain regions.

The 2024 Lancet Diabetes & Endocrinology analysis of semaglutide trial data found small but measurable improvements in quality-of-life mood subscales among users. The effects weren’t large but were consistent across subgroups.

A 2023 analysis of GLP-1 use and dementia risk in JAMA Neurology suggested possible neuroprotective effects in observational data, with implications for cognitive trajectories that overlap with depression.

A specific dedicated trial of semaglutide for major depressive disorder is in progress as of 2025. Results haven’t been published as of the date of this article. If positive, GLP-1s could become a treatment option for depression specifically, not just an adjunct for weight in patients with depression.

Mechanistic studies in animals show GLP-1 receptor activation affects reward processing, anxiety circuits, and stress reactivity. Translation to humans is unclear.

The anhedonia reports from a small subset of patients remain anecdotal but are consistent enough to warrant continued attention.

Key Takeaway: The SMILES trial (Jacka 2017) showed 32% remission from major depression with Mediterranean dietary intervention versus 8% with social support.

Other Relevant Evidence

Postpartum depression and weight: A 2018 meta-analysis in Journal of Affective Disorders found postpartum depression correlates with higher postpartum weight retention. Bidirectional effects likely.

Inflammation hypothesis: The Raison 2013 trial in JAMA Psychiatry tested infliximab (TNF-alpha blocker) in treatment-resistant depression. The whole sample didn’t benefit, but a subgroup with elevated CRP did, supporting a role for inflammation-targeted approaches in select patients.

Omega-3 fatty acids: The Mocking 2016 meta-analysis in Translational Psychiatry pooled 13 trials and found small to moderate antidepressant effects of EPA-dominant omega-3 supplementation.

Vitamin D: The 2020 VITAL-DEP trial in over 18,000 adults found no depression prevention benefit from vitamin D in a generally non-deficient population. Smaller trials in deficient patients suggest correction may improve mood.

Sleep and depression: Multiple cohort studies including the 2011 Sleep Medicine Reviews analysis show insomnia is both a symptom and predictor of depression. Treating insomnia with CBT-I improves depression outcomes independent of antidepressant treatment.

Bupropion and weight: The Anderson 2002 trial demonstrated bupropion’s weight-loss potential in non-depressed obese patients, contributing to the rationale for its inclusion in the naltrexone-bupropion combination (Contrave) for weight loss.

Subgroup Findings That Change Clinical Decisions

Beyond headline results, several major studies produced subgroup findings that inform individual patient decisions. These details often matter more than the main effect for any given patient.

Luppino subgroups: The bidirectional risk was stronger in women than men. The depression-to-obesity direction was stronger for unipolar depressive disorder than for milder depressive symptoms. Effects were consistent across age groups but more pronounced in studies with longer follow-up, suggesting cumulative effects over time.

Domecq subgroups: Weight effects were larger in studies lasting more than 12 months than in shorter trials. Patients with higher baseline BMI gained less additional weight on most antidepressants, possibly reflecting ceiling effects or different underlying biology. Combination antidepressant regimens (SSRI plus mirtazapine, for example) showed additive weight effects, not protective ones.

SMILES sensitivity analyses: Response rates were highest in patients with the largest dietary improvements at 12 weeks, supporting a dose-response relationship between dietary change and depression outcomes. Patients on antidepressants and those not on antidepressants both responded to the dietary intervention, suggesting the benefit was independent of pharmacotherapy.

**STAR*D special populations:** Black and Hispanic patients had slightly lower remission rates than white patients across treatment levels, even after adjusting for socioeconomic factors. Patients with melancholic features had higher response rates to medication switches than to augmentation strategies.

Cooney exercise subgroups: Effects were similar between aerobic and resistance training. Group-based exercise showed slightly larger effects than individual exercise, possibly reflecting social support contributions. Effects were larger in supervised programs than unsupervised ones.

Adams bariatric subgroups: Suicide risk was concentrated in the first three years post-surgery. Patients with prior psychiatric history had the highest absolute risk. Roux-en-Y gastric bypass and adjustable gastric banding showed similar patterns.

How Does the Evidence Compare Across Treatment Modalities?

The following comparisons summarize effect sizes across major intervention types. Effect size 0.2 is considered small, 0.5 medium, and 0.8 large in standardized terms.

Intervention	Effect size (SMD)	Source
SSRI antidepressant vs placebo	0.30-0.40	Cipriani 2018 Lancet network meta-analysis
Bupropion vs placebo	0.30-0.40	Cipriani 2018 Lancet
TCAs vs placebo	0.40-0.50	Cipriani 2018 Lancet
CBT vs control	0.50-0.70	Cuijpers meta-analyses
Behavioral activation vs control	0.50-0.70	Ekers 2014 meta-analysis
MBCT vs treatment as usual (relapse)	21% relative reduction	Kuyken 2016 JAMA Psychiatry
Aerobic exercise vs control	0.40-0.62	Cooney 2013 Cochrane / Singh 2023 BJSM
Resistance training vs control	0.66	Gordon 2018 JAMA Psychiatry
Mediterranean diet (SMILES)	1.16	Jacka 2017 BMC Medicine
Light therapy for SAD	0.50-0.80	Golden 2005 Am J Psychiatry
TMS vs sham	0.55	Health Quality Ontario 2016
Esketamine + antidepressant	0.30-0.40	Daly 2018 JAMA Psychiatry

These effect sizes shouldn’t be compared in isolation. Trial designs, populations, and outcome measures differ. But the rough ranking gives clinicians and patients a sense of expected magnitudes.

How Does the Inflammation Hypothesis Hold Up?

The inflammation hypothesis proposes that chronic low-grade inflammation contributes to a subgroup of depression cases. The evidence is mixed but points to a real subgroup effect rather than a universal explanation.

The Raison 2013 trial in JAMA Psychiatry tested infliximab in 60 patients with treatment-resistant depression. The whole-sample analysis showed no significant benefit. However, patients with baseline CRP above 5 mg/L showed substantial improvement compared with placebo. Patients with low CRP showed numerically worse outcomes on the active drug.

Subsequent work has supported a role for inflammation in some patients. The Kohler-Forsberg 2019 meta-analysis in Acta Psychiatrica Scandinavica pooled 36 trials of anti-inflammatory agents for depression and found small overall effects, with larger effects in patients with elevated baseline inflammation.

The Strawbridge 2015 Translational Psychiatry analysis suggested approximately 30-40% of patients with major depression have elevated inflammatory markers. This subgroup may benefit from anti-inflammatory approaches, including dietary interventions, exercise, weight loss, and possibly targeted medications.

For weight specifically, obesity is associated with chronic low-grade inflammation. Weight loss reduces CRP and IL-6 levels in proportion to weight reduction. The shared inflammation may explain some of the bidirectional risk Luppino documented.

How Do GLP-1 Mechanisms Relate to Mood?

GLP-1 receptor agonists may affect mood through multiple pathways including direct CNS receptor activation, peripheral inflammation reduction, weight loss benefits, and metabolic improvements. Each pathway has supporting preclinical or early clinical evidence.

Direct CNS effects: GLP-1 receptors are expressed in brain regions including the hippocampus, amygdala, nucleus accumbens, and ventral tegmental area. These regions are involved in mood regulation, reward processing, and stress responses. Animal studies show GLP-1 agonist effects on depression-like behaviors in rodent models.

Inflammation reduction: Semaglutide and other GLP-1 agonists reduce CRP, IL-6, and TNF-alpha in clinical trials. The reduction is partly weight-loss-dependent and partly direct. For inflammation-driven depression subgroups, this could produce mood benefits.

Weight loss benefits: Substantial weight loss improves depression scores in many studies. Mechanisms include reduced joint pain, better sleep, improved self-image, and easier physical activity. The Bocchio-Chiavetto 2018 meta-analysis suggested weight loss interventions reduce depression scores by approximately 0.5 standardized units.

Metabolic improvements: Improved insulin sensitivity, better glucose control, and reduced cardiovascular risk all correlate with mood improvements in observational studies. Whether these are causal or epiphenomenal isn’t fully resolved.

The flat affect or anhedonia some patients report on GLP-1s could reflect dopamine pathway effects. Reward processing changes that quiet food noise might also dampen other reward responses. This remains anecdotal in the published literature.

What the Evidence Doesn’t Yet Answer

Several important questions remain open:

• Long-term outcomes of GLP-1 use in patients with severe depression history
• Optimal sequencing of GLP-1s and antidepressants in newly diagnosed comorbid patients
• Whether GLP-1s have direct antidepressant effects independent of weight loss
• How to predict which patients will experience flat affect or anhedonia on GLP-1s
• Long-term durability of dietary interventions for depression beyond 12 weeks
• Optimal exercise dose and modality for depression with comorbid obesity
• Effects of GLP-1 discontinuation on mood in patients with prior depression

These questions are active research areas. Practice will continue to evolve as evidence accumulates.

The Bottom Line

The clinical evidence supports an integrated approach to depression and weight that combines pharmacotherapy, psychotherapy, lifestyle interventions, and weight-targeted treatments where appropriate. The bidirectional risk between depression and obesity is real and substantial. Drug choice meaningfully affects weight outcomes. Diet, exercise, and sleep have measurable mood effects. GLP-1 medications appear safe to use in patients with depression history.

For clinicians and patients navigating these conditions together, the evidence supports specific choices: weight-friendly antidepressants when feasible, structured lifestyle interventions, and GLP-1 medications for selected patients with appropriate monitoring.

If you’re in crisis, please call or text 988.

Bottom line: The FDA’s January 2024 review found no causal link between GLP-1 medications and suicidality.

Myth vs. Fact: Setting the Record Straight

Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.

Myth: Antidepressants always cause weight gain. Fact: Drug choice matters. Paroxetine, mirtazapine, and olanzapine cause significant gain. Bupropion (Wellbutrin) is often weight-neutral or weight-loss. Vortioxetine is relatively neutral. Talk to your prescriber about weight-friendly options.

Myth: GLP-1 medications cause depression. Fact: The FDA reviewed this in early 2024 and found no causal link to suicidality. NIH 2024 retrospective data actually showed lower suicidal ideation on semaglutide vs other anti-obesity medications. Some patients report ‘flattened mood,’ but it’s not the same as clinical depression.

Myth: If you’re depressed, focus on mental health first, then weight. Fact: Bidirectional research (Luppino 2010 meta-analysis) shows depression and obesity worsen each other. Treating both simultaneously, with medications that don’t conflict, is now standard of care.

The Path Forward with TrimRx

Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing depression and weight and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.

At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24/7 support you deserve.

Our program includes:

• Doctor consultations: professional guidance without the in-person waiting room
• Lab work coordination: baseline health markers monitored properly
• Ongoing support: 24/7 access to specialists for dosage changes and side effect management
• Reliable medication access: FDA-registered, inspected compounding pharmacies prepare Compounded Semaglutide or Compounded Tirzepatide when branded medications aren’t the right fit

Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.

Bottom line: TrimRx provides a streamlined, medically supervised path to access the latest advancements in depression and weight and weight management, all from the comfort of home.

FAQ

Are These Studies Generalizable to All Populations?

Most major studies have been conducted in North American, European, or Australian populations. Generalizability to other populations is plausible but not always tested. Sex differences exist for several of the relationships described (Luppino’s findings were stronger in women, for example).

How Can I Evaluate New Claims About Depression and Weight?

Look for randomized controlled trials with adequate sample sizes, peer-reviewed publication in established journals, replication in independent samples, and reasonable effect sizes. Be cautious of single studies, observational claims of large effects, and supplement industry-funded research without independent replication.

Is Bariatric Surgery Still Recommended Given the Suicide Data?

Yes for eligible patients with appropriate psychiatric screening and post-surgical support. The overall mortality benefit is substantial, but the suicide risk is real and requires attention. Patients with active mental health concerns generally need stabilization before surgery.

Should I Take Supplements Based on These Studies?

Vitamin D for documented deficiency, EPA-dominant omega-3s for mild-moderate depression as adjunct, and B12 if levels are low are reasonable. Most other supplements lack the evidence to recommend routinely. Discuss with your clinician.

Does the Evidence Support Trying Lifestyle Changes Before Medication?

For mild to moderate depression, yes. Therapy, exercise, dietary changes, and sleep treatment can be effective standalone interventions. For severe depression, combination treatment from the start has better outcomes.

Is There Evidence for or Against GLP-1s for Depression as a Primary Indication?

Not yet sufficient. Animal studies and mechanistic considerations suggest possibility. Observational data on mood are encouraging but not conclusive. A randomized trial of semaglutide for depression is in progress.

How Reliable Are the Antidepressant Weight Rankings From Domecq?

The rankings reflect average effects across diverse populations and trial designs. Individual responses vary substantially. A patient may gain weight on bupropion or lose weight on paroxetine, contrary to averages. The rankings are useful for first-line drug selection but shouldn’t override individual experience.

Why Have Some STAR*D Reanalyses Been Controversial?

The Pigott 2023 BMJ Mental Health reanalysis applied stricter outcome criteria, including requiring sustained remission and excluding certain patient categories from the primary analysis. The reanalysis found cumulative remission rates closer to 35% rather than the 67% originally reported. The original investigators have disputed the methodology. The clinical implication is that real-world depression treatment may be less effective than the original headline numbers suggested.

Does the FDA’s 2024 GLP-1 Review Apply to All GLP-1 Medications?

The review covered the class of GLP-1 receptor agonists including semaglutide, liraglutide, tirzepatide (a dual GIP/GLP-1 agonist), and others. The conclusions applied broadly. Subsequent observational data have included most class members and pointed in similar directions.

Is the SMILES Trial Replicable?

Partially. The HELFIMED trial in 152 adults showed similar directional effects, with smaller magnitude. The AMMEND trial in young adults reproduced the benefit in a different population. The MooDFOOD trial focused on prevention rather than treatment and didn’t show benefit, but it tested supplements and food-related behavioral activation rather than full dietary change. The dietary-change-as-treatment finding has held up across replications, though effect sizes have been somewhat smaller than the original SMILES result.

Does Exercise Work as Well in Severe Depression?

Effect sizes have been somewhat smaller in severe depression than in mild to moderate cases. The Singh 2023 BJSM umbrella review found benefit across severity levels but largest effect sizes in mild to moderate populations. For severe depression, exercise is best used adjunctively rather than as monotherapy.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.